Devgen

Devgen (EBR:DEVG) Zwijnaarde, Belgium (17 November 2008) - Devgen NV announces to have received today the following shareholder notification:

Devgen (EBR:DEVG) Webcast and conference call on Friday 14 November 2007 at 12.00 am. A link is available on Devgen's home page www.devgen.com and participation in the conference call is possible via the number +32 (0)2 290 14 07.

Devgen (EBR:DEVG) In November 2007, Devgen announced its intent to divest its pharma unit in order to focus on its agro-activities. Through its research activities in Belgium, Devgen has developed a unique technology position in crop protection and has grown to a fully integrated trait and seed business in Asian growth markets, with a focus on rice, sorghum, sunflower and pearl millet and a licensing business in other crops. Devgen's pharma division focuses on the development of a novel class of preclinical drug candidates for the treatment of inflammatory diseases.

Devgen (EBR:DEVG) Gent (Belgium) - Regulatory Release - Transparency declarations from the major shareholders of Devgen NV

Devgen (EBR:DEVG) Gent (Belgium) - Regulatory Release - September 12, 2008, Devgen NV (Euronext Brussels: DEVG) publishes required information in accordance with new transparency legislation (Belgian Act of May 2, 2007) on disclosure of major holdings in issuers whose shares are admitted to trading on a regulated Belgian market.

Devgen (EBR:DEVG) Zwijnaarde, 26 August 2008 - Devgen NV (Euronext: DEVG) has successfully entered the hybrid seed market and is ready for expansion.